Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy
Rong Fu,1 Chuan-Qing Jing,1 Xiu-Rong Li,2 Zhao-Feng Tan,2 Hui-Jie Li2 1Clinical Department of Integrated Traditional Chinese and Western Medicine, The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, People’s Republic of China; 2Affiliated Hospi...
Main Authors: | Fu R, Jing CQ, Li XR, Tan ZF, Li HJ |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-06-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/prognostic-significance-of-serum-pd-l1-level-in-patients-with-locally--peer-reviewed-fulltext-article-CMAR |
Similar Items
-
Perioperative immunotherapy for esophageal squamous cell carcinoma
by: Dan D. Wei, et al.
Published: (2024-02-01) -
SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study
by: Lan Mu, et al.
Published: (2021-05-01) -
Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy
by: Xiaolu Ma, et al.
Published: (2022-11-01) -
CD155 Cooperates with PD-1/PD-L1 to Promote Proliferation of Esophageal Squamous Cancer Cells via PI3K/Akt and MAPK Signaling Pathways
by: Xiyang Tang, et al.
Published: (2022-11-01) -
Chemoimmunotherapy for esophageal squamous cell carcinoma—Summary and discussion of recent clinical trials
by: Zhen Zhang, et al.
Published: (2023-06-01)